Corpus Intelligence IC Memo — CHELSEA HOSPITAL 2026-04-26 14:09 UTC
IC Memo — CHELSEA HOSPITAL
Investment Committee Memorandum | MI | 79 beds | Grade C | EBITDA uplift $13.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

CHELSEA HOSPITAL

CCN 230259 | WASHTENAW, MI | 79 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

CHELSEA HOSPITAL is a 79-bed suburban community hospital in WASHTENAW, MI with $187.8M in net patient revenue and a -1.1% operating margin. The hospital serves a payer mix of 35.0% Medicare, 1.2% Medicaid, and 63.8% commercial.

Thesis: Turnaround. Our ML models identify $13.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -1.1% to 6.3% (+736bps).

Net Revenue HCRIS$187.8M
Current EBITDA COMPUTED$-2.0M
Operating Margin COMPUTED-1.1%
Occupancy HCRIS47.1%
Revenue / Bed COMPUTED$2.4M
Net-to-Gross HCRIS26.8%
Distress Probability ML46.2%

2. Market Context & Competitive Position

163
MI Hospitals
-5.2%
State Median Margin
53
Comparable Hospitals

MI has 163 Medicare-certified hospitals with a median operating margin of -5.2%. The target's margin of -1.1% places it above the state median. Among 53 size-comparable peers (40-158 beds), the median margin is -4.7%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (40-158), prioritizing same-state peers. 53 hospitals in the comp set.

HospitalStateBedsRevenueMargin
CHELSEA HOSPITAL (Target)MI79$187.8M-1.1%
KARMANOS CANCER HOSPITALMI106$284.8M-27.8%
BRONSON BATTLE CREEKMI144$251.8M-27.7%
ASCENSION PROVIDENCE ROCHESTERMI153$249.9M-4.6%
MYMICHIGAN MEDICAL CENTER ALPEMI128$237.2M6.0%
MEMORIAL HEALTHCAREMI113$226.4M-13.4%
MCLAREN OAKLANDMI107$214.4M1.6%
TRINITY HEALTH LIVINGSTONMI42$200.4M15.2%
BEAUMONT HOSPITAL - TAYLORMI99$184.3M-0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.9M+210bp18mo
Cost to Collect4.5%2.5%$3.8M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.3M+122bp9mo
Clean Claim Rate88.0%96.0%$120K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.9M
Cost to Collect
$3.8M
Denial Rate Reduction
$3.7M
A/R Days Reduction
$2.3M
Clean Claim Rate
$120K
Total EBITDA Uplift$13.8M
Current EBITDA$-2.0M
+ RCM Uplift+$13.8M
Pro Forma EBITDA$11.8M
Current Margin-1.1%
Pro Forma Margin6.3%
WC Released (1x)$7.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-3.0M$125.2M0.00x-100.0%
Base (11x exit)10.0x11.0x$-3.0M$136.7M0.00x-100.0%
Bull Case9.0x11.0x$-2.7M$181.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.7M$197.1M0.00x-100.0%
Bear Case11.0x10.0x$-3.3M$57.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-3.3M$61.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 53 hospitals with 40-158 beds
  • Same-state prioritization (n=54)
  • Comp margins: P25=-13.7% / P50=-4.7% / P75=5.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.